
Nuvation Bio (NUVB) Stock Forecast & Price Target
Nuvation Bio (NUVB) Analyst Ratings
Bulls say
Nuvation Bio Inc. demonstrates a strong positive outlook due to the robust efficacy profile of its lead product candidate, taletrectinib, which achieved an 88.8% confirmed overall response rate and extends median duration of response and progression-free survival significantly in TKI-naive ROS1+ non-small cell lung cancer (NSCLC) patients. The company's financial position is solidified by ending 2024 with $502.7 million in cash, cash equivalents, and marketable securities, which is expected to support operations until reaching profitability. Furthermore, the anticipated market penetration of 35% in the first-line setting aligns with revised NCCN guidelines, positioning Nuvation Bio favorably in the competitive oncology landscape.
Bears say
Nuvation Bio faces significant risks that could adversely impact its financial performance, including the potential for negative clinical proof-of-concept data for its therapeutic candidates, which could hinder progress in obtaining necessary approvals. Additionally, there is concern regarding the commercial uptake of its lead product, taletrectinib, which may be adversely affected by intense competition and other market dynamics, leading to projected financial losses. The company's recent financial results show a net loss of $0.15 per share for Q4 2024, with forecasts for 2025 indicating a further increased loss, suggesting a deteriorating financial outlook.
This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.
Nuvation Bio (NUVB) Analyst Forecast & Price Prediction
Start investing in Nuvation Bio (NUVB)
Order type
Buy in
Order amount
Est. shares
0 shares